HOME >> BIOLOGY >> NEWS
Horse genome assembled

BETHESDA, Md., Wed., Feb. 7, 2007 The first draft of the horse genome sequence has been deposited in public databases and is freely available for use by biomedical and veterinary researchers around the globe, leaders of the international Horse Genome Sequencing Project announced today.

The $15 million effort to sequence the approximately 2.7 billion DNA base pairs in the genome of the horse (Equus caballus) was funded by the National Human Genome Research Institute (NHGRI), one of the National Institutes of Health (NIH). A team led by Kerstin Lindblad-Toh, Ph.D., at the Eli and Edythe L. Broad Institute of the Massachusetts Institute of Technology and Harvard University, in Cambridge, Mass., carried out the sequencing and assembly of the horse genome.

Approximately 300,000 Bacterial Artificial Chromosome (BAC) end sequences, which provide continuity when assembling a large genome sequence, were contributed to the horse sequencing project by Ottmar Distl, D.V.M., Ph.D. and Tosso Leeb, Ph.D., from the University of Veterinary Medicine, in Hanover, Germany and Helmut Blcker, Ph.D., from the Helmholtz Centre for Infection Research in Braunschweig, Germany. Production of the BAC end sequences was funded by the Volkswagen Foundation and the State of Lower Saxony.

Sequencing of the domestic horse genome began in 2006, building upon a 10-year collaborative effort among an international group of scientists to use genomics to address important health issues for equines, known as the Horse Genome Project (www.uky.edu/Ag/Horsemap/). The horse whose DNA was used in the sequencing effort is a Thoroughbred mare named Twilight from Cornell University in Ithaca, N.Y. Researchers obtained the DNA from a small sample of the animal's blood. To download a high-resolution photo of Twilight, go to http://www.genome.gov/pressDisplay.cfm?photoID=
'"/>


Contact: Geoff Spencer
spencerg@mail.nih.gov
301-402-0911
NIH/National Human Genome Research Institute
7-Feb-2007


Page: 1 2 3

Related biology news :

1. Horse antibodies against the bird flu virus H5N1 are effective as treatment in mice
2. Horseshoe crab decline threatens shorebird species
3. Horse auction raises $75,000 for research
4. Unravelling new complexity in the genome
5. One species, many genomes
6. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
7. Charting ever-changing genomes
8. Neutral evolution has helped shape our genome
9. Sea anemone genome provides new view of our multi-celled ancestors
10. Cloning the male genome may help infertile men
11. Mutating the entire genome

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Horse genome assembled

(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
Cached News: